| A-71623CCK1 agonist |
Sample solution is provided at 25 µL, 10mM.
Nature.2017 Jan 19;541(7637):417-420.
Nature.2018 Nov;563(7731):407-411.Nature.2018 Jun 13.Nature.2018 Jun 27.Nature.2018 Mar 29;555(7698):673-677.Nature.2017 Sep 7;549(7670):96-100.Nature.2016 Apr 21;532(7599):398-401.
Science.2016 Aug 5;353(6299)594-8Nat Nanotechnol.2017 Dec;12(12):1190-1198.Nature Biotechnology.2017 Jun;35(6):569-576Nat Med.2018 Sep 17.Cell.2018 Dec 21. pii: S0092-8674(18)31561-7.Cell.Available online 25 October 2018.Cell.2018 Sep 27. pii: S0092-8674(18)31183-8.Cell.2018 Jun 28;174(1):172-186.e21.Cell.2018 Feb 22;172(5):1007-1021.e17.Cell.2017 Nov 30;171(6):1284-1300.e21.Cell.2017 Aug 17. pii: S0092-8674(17)30869-3.Cell.2017 Jul 13;170(2):312-323Nat Med.2018 Jan 29.Nat Med.2017 Nov;23(11):1342-1351.Cell.2017 Apr 6;169(2):286-300.Cell.2015 Aug 27;162(5):987-1002.Cell.2015 Feb 12;160(4):729-44.Nature Medicine.2017 Apr;23(4):493-500.Cancer Cell.2018 May 14;33(5):905-921.e5.Cancer Cell.2018 Apr 9;33(4):752-769.e8.Cancer Cell.2018 Mar 12;33(3):401-416.e8.Cancer Cell.2017 Aug 14;32(2):253-267.e5.Nat Methods.2018 Jul;15(7):523-526.Cell Stem Cell.2018 May 3;22(5):769-778.e4.Cell Stem Cell.2017 Nov 20. pii: S1934-5909(17)30375-2.Quality Control & MSDS
- View current batch:
- Purity = 98.00%
- COA (Certificate Of Analysis)
- MSDS (Material Safety Data Sheet)
- Datasheet
Chemical structure
A-71623 Dilution Calculator
calculate
A-71623 Molarity Calculator
calculate
| Cas No. | 130408-77-4 | SDF | Download SDF |
| Chemical Name | (6S,9S,12S)-6-((1H-indol-3-yl)methyl)-12-(((S)-1-amino-1-oxo-3-phenylpropan-2-yl)(methyl)carbamoyl)-2,2-dimethyl-4,7,10-trioxo-9-(4-(3-(o-tolyl)ureido)butyl)-3-oxa-5,8,11-triazatetradecan-14-oic acid | ||
| Canonical SMILES | O=C([C@H](CCCCNC(NC1=CC=CC=C1C)=O)NC([C@H](CC2=CNC3=CC=CC=C23)NC(OC(C)(C)C)=O)=O)N[C@@H](CC(O)=O)C(N(C)[C@H](C(N)=O)CC4=CC=CC=C4)=O | ||
| Formula | C44H56N8O9 | M.Wt | 840.97 |
| Solubility | Soluble to 1 mg/ml in 20mM PBS buffer | Storage | Desiccate at -20°C |
| Physical Appearance | White lyophilised solid | Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. | ||
A-71623 is a selective agonist of CCKA receptor with an IC50 value of 3.7 nM in guinea pig pancreas [1, 2].
CCKA receptors belong to a subtype of cholecystokinin (CCK) receptors in the brain. CCK is a type of neuropeptide present throughout the central nervous system. CCK can act as a neurotransmitter in both normal and abnormal brain. CCK receptors exist in two forms in the brain. Another subtype of CCK receptors is CCKB subtype [1].
In NCI-H345 cells possessing CCKB/gastrin receptors, A-71623 was weak and behaved as a partial agonist in calcium studies [2]. A-71623 had very low affinity to CCK binding sites in C6 cells with an IC50 value of 1236 ± 81 nM [3]. It is hard to find the CCKA response result of the application of A-71623 in cells.
In radioligand binding assays, A-71623 showed IC50 values of 3.7 nM for CCKA in guinea pig pancreas and 4500 nM for CCKB in cerebral cortex. Data showed that A-71623 was an agonist in stimulating the release of pancreatic amylase, and this stimulatory effect was potently inhibited by L-364,718, a CCKA antagonist. Data showed that A-71623 acted as a full agonist in stimulating the breakdown of phosphoinositide in pancreas. In the ileum, A-71623 was also a potent agonist in stimulating CCKA receptors. In guinea pig gastric glands, the affinity of A-71623 for the CCK-B/gastrin receptor was 11 µM. This result demonstrated that A-71623 should be a potent and selective agonist at CCKA receptors [2].
References: [1]. Gracey DJ, Bell R, King DJ. Differential effects of the CCKA receptor ligands PD-140,548 and A-71623 on latent inhibition in the rat. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2002, 26(3): 497-504.[2]. Lin CW, Shiosaki K, Miller TR, et al. Characterization of two novel cholecystokinin tetrapeptide (30-33) analogues, A-71623 and A-70874, that exhibit high potency and selectivity for cholecystokinin-A receptors. Molecular pharmacology, 1991, 39(3): 346-351.[3]. Kaufmann R, Lindschau C, Scho T, et al. Type B cholecystokinin receptors on rat glioma C6 cells. Binding studies and measurement of intracellular calcium mobilization. Brain research, 1994, 639(1): 109-114.
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
1.若都为正常，那么并未有太大问题，只要定期复查就可以了。
2.如果TGAb、TMAb、甲状腺功能均高，那么就是桥本氏甲状腺炎并甲亢，需要抗甲亢治疗。
3.如果TGAb、TMAb高，甲状腺功能下降，那么就是桥本氏甲状腺炎并甲减，需要进行甲减治疗。
4.如果TGAb、TMAb高，甲状腺功能正常，那么就是桥本氏甲状腺炎，无需特殊治疗，只要定期复查甲状腺功能就可能以了，不过这种情况有可能以后演变成甲减或者甲亢。
1.若都为正常，那么并未有太大问题，只要定期复查就可以了。
2.如果TGAb、TMAb、甲状腺功能均高，那么就是桥本氏甲状腺炎并甲亢，需要抗甲亢治疗，那么，要注意戒碘饮食，避免吃一些含碘丰富的食物，如海产品等。
3.如果TGAb、TMAb高，甲状腺功能下降，那么就是桥本氏甲状腺炎并甲减，需要进行甲减治疗，饮食方面可以增加含碘丰富的食物摄入。
4.如果TGAb、TMAb高，甲状腺功能正常，那么就是桥本氏甲状腺炎，无需特殊治疗，只要定期复查甲状腺功能就可能以了，不过这种情况有可能以后演变成甲减或者甲亢。
1.若都为正常，那么并未有太大问题，只要定期复查就可以了。
2.如果TGAb、TMAb、甲状腺功能均高，那么就是桥本氏甲状腺炎并甲亢，需要抗甲亢治疗。
3.如果TGAb、TMAb高，甲状腺功能下降，那么就是桥本氏甲状腺炎并甲减，需要进行甲减治疗。
4.如果TGAb、TMAb高，甲状腺功能正常，那么就是桥本氏甲状腺炎，无需特殊治疗，只要定期复查甲状腺功能就可能以了，不过这种情况有可能以后演变成甲减或者甲亢。
